ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Dave Levitan

Dave Levitan

Posts by Author

A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer.

The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.

Adding midostaurin to chemotherapy prolonged survival in younger adult patients with acute myeloid leukemia and a FLT3 mutation, according to a randomized trial.

Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.

The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma.

The PD-L1 inhibitor atezolizumab showed substantial responses as a single-agent treatment in patients with advanced non–small-cell lung cancer with confirmed PD-L1 expression.

Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer.

Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma.

Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.